Abstract
Despite advances in the treatment of mCRC, chemotherapy resistance is present or develops in most pts and overcoming this constitutes a highly unmet medical need. Onvansertib (Onv), is a highly specific PLK1 inhibitor, that demonstrated preliminary safety and efficacy in combination with FOLFIRI/bev in 2L treatment of mKRAS mCRC pts with no prior irinotecan treatment (Lenz et al, JCO 2022). Here we tested the potential of Onv to overcome resistance to irinotecan-based therapies in CRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
